Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment
The prevalence of cognitive dysfunction in diabetic patients is high, which seriously affects the quality of life of patients, and early intervention is of great significance. Central nervous system insulin resistance plays a key role in the pathogenesis of cognitive dysfunction in diabetic patients. Central insulin resistance observed by functional magnetic resonance imaging (fMRI), may serve as an alternative endpoint for assessing cognitive function. Sodium glucose cotransporter 2 inhibitor (SGLT2i) may improve…
Conditions studied
Type 2 Diabetes Mellitus, Cognitive Impairment
About this study
The prevalence of cognitive dysfunction in diabetic patients is high, which seriously affects the quality of life of patients, and early intervention is of great significance. Central nervous system insulin resistance plays a key role in the pathogenesis of cognitive dysfunction in diabetic patients. Central insulin resistance observed by functional magnetic resonance imaging (fMRI), may serve as an alternative endpoint for assessing cognitive function. Sodium glucose cotransporter 2 inhibitor (SGLT2i) may improve cognitive impairment by improving central insulin resistance.
Interventions
- Drug: Canagliflozin group — Canagliflozin,100mg once daily, orally, for 6 months
- Drug: Sitagliptin — Sitagliptin,100mg once daily, orally, for 6 months
- Drug: Acarbose — Acarbose,100mg three times daily, orally, for 6 months
Primary outcomes
- the changes in cerebral blood flow shown by fMRI (6 months)
Eligibility information
Study locations
- Fudan University affiliated Huadong Hospital, Shanghai, Shanghai Municipality China
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.